McKesson Corporation (MCK) Earnings

McKesson Corporation

MCK · NYSE

Jun 2026upcoming

Next quarter

Consensus is $9.44 EPS for Jun 2026 across 5 estimates, ranging $9.25 to $9.65.

MCK Mar 2026

Reported May 7, 2026

Beat 1.12%

EPS estimate: $11.56
EPS actual: $11.69
Revenue estimate: —
Revenue actual: —
1-day move: -2.47%

Call highlights have not been generated for this quarter.

Symbol: MCK
Type: Stock
Sector: Health Care
Industry: Other Pharmaceuticals
Country: North America
Exchange: NYSE

McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to help make quality care more accessible and affordable. Learn more about how McKesson is impacting virtually every aspect of healthcare at McKesson.com and read Stories & Insights.

Key Issues

Bullish view

Specialty pharmaceuticals and oncology growth are highlighted as sources of momentum, while specialty demand can support earnings even if reported revenue growth is tempered.

Bearish view

Pricing dynamics, including potential GLP-1 drug pricing pressure, could reduce the benefit of volume and specialty growth and weigh on margins or earnings expectations.

Analyst Consensus

See all

Buy

17 analysts

$849

Current

$925

Low

$950

Average

$925

High

Average target implies +11.83% versus the current price.

Earnings History

BeatMissNo estimate

Peers

GSK plc American Depositary Shares (Each representing two Ordinary Shares)